Eagle Strategies LLC Buys 23 Shares of Eli Lilly and Company (NYSE:LLY)

Eagle Strategies LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,098 shares of the company’s stock after acquiring an additional 23 shares during the period. Eagle Strategies LLC’s holdings in Eli Lilly and Company were worth $640,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Morgan Stanley boosted its stake in Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after buying an additional 83,915 shares in the last quarter. Northern Trust Corp boosted its stake in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after buying an additional 355,317 shares in the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company in the fourth quarter worth approximately $3,416,206,000. Finally, International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 12,344 shares of the firm’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $634.13, for a total transaction of $7,827,700.72. Following the completion of the transaction, the insider now directly owns 99,543,810 shares in the company, valued at $63,123,716,235.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 146,129 shares of company stock worth $94,364,735 over the last three months. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $700.00.

Eli Lilly and Company Stock Up 0.6 %

Shares of NYSE:LLY traded up $4.74 on Wednesday, hitting $761.98. 1,658,285 shares of the company traded hands, compared to its average volume of 3,133,610. Eli Lilly and Company has a 52 week low of $363.33 and a 52 week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a 50 day simple moving average of $755.79 and a 200-day simple moving average of $649.71. The company has a market cap of $724.00 billion, a PE ratio of 131.65, a PEG ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period last year, the company earned $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.